Jonathan A. Young1
Shouan Zhu1,2,3
Edward O. List4Silvana Duran-Ortiz4
Yosri Slama4
Darlene E. Berryman3,4*- 1Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, United States
- 2Ohio Musculoskeletal and Neurological Institute, Heritage College of Osteopathic Medicine, Athens, OH, United States
- 3Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, United States
- 4Edison Biotechnology Institute, Ohio University, Athens, OH, United States
Growth hormone (GH) is a peptide hormone that can signal directly through its receptor or indirectly through insulin-like growth factor 1 (IGF-1) stimulation. GH draws its name from its anabolic effects on muscle and bone but also has distinct metabolic effects in multiple tissues. In addition to its metabolic and musculoskeletal effects, GH is closely associated with aging, with levels declining as individuals age but GH action negatively correlating with lifespan. GH’s effects have been studied in human conditions of GH alteration, such as acromegaly and Laron syndrome, and GH therapies have been suggested to combat aging-related musculoskeletal diseases, in part, because of the decline in GH levels with advanced age. While clinical data are inconclusive, animal models have been indispensable in understanding the underlying molecular mechanisms of GH action. This review will provide a brief overview of the musculoskeletal effects of GH, focusing on clinical and animal models.
1 Introduction
Growth hormone (GH) is a peptide hormone commonly known for its role in development and bone and muscle growth. GH is synthesized by somatotrophs in the anterior pituitary, and its secretion is regulated mainly by two hypothalamic hormones, growth hormone releasing hormone (GHRH) and somatostatin, with GHRH increasing and somatostatin decreasing GH secretion, as well as by diet, exercise, stress, and other factors (Caputo et al., 2021). Once secreted, GH circulates and binds to the pre-dimerized GH receptor (GHR) (Brooks and Waters, 2010) on target cells. Receptor binding results in a signaling cascade primarily through Janus Kinase 2 (JAK2) and STAT5. However, other pathways, such as mitogen-activated protein kinases (MAPK) and phosphoinositide 3-kinase (PI3K) pathway (Brooks and Waters, 2010), can also be activated by GH. As for function, GH not only promotes linear postnatal growth and bone growth but also influences metabolism of lipids, carbohydrates, nitrogen, and minerals. Among many favorable tissue-dependent actions, GH is well established to increase muscle mass, reduce adipose tissue through lipolysis, and augment gluconeogenesis in the liver (Olarescu et al., 2000). A notable unwanted action of GH is its ability to inhibit insulin action also known as its diabetogenic activity (Houssay and Biasiotti, 1931).
Importantly, GHR activation stimulates expression of another potent hormone, insulin-like growth factor 1 (IGF-1) in target tissues (Hellstrom et al., 2017). Because of this, GH’s effects on tissues can be either direct, indirect via IGF-1, or both direct and indirect (Kopchick and Andry, 2000). For example, GH has been reported to be responsible for ∼14% of longitudinal growth, IGF-1 is responsible for ∼35% (Lupu et al., 2001), and the combined effect of GH and IGF-1 accounts for 34% of growth (and 17% of total mouse growth regulated by other factors). Thus, both GH and IGF-1 have independent and synergistic effects depending on the tissue (Olarescu et al., 2000). IGF-1 shares many intracellular signaling pathways with GH, also activating MAPK and PI3k through insulin receptor substrate 1 (IRS1), and crosstalk between the two pathways has been reported in beta cells (Ma et al., 2011), highlighting the complexity of GH action on target tissues such as muscle and bone.
Although pituitary-derived endocrine GH is a key driver of the musculoskeletal effects of GH, locally produced autocrine/paracrine GH, also known as extrapituitary GH, also plays a major role in the growth and development of muscle and bone (Harvey, 2010). Evidence for the local production of GH is the increased (relative to serum) concentration of GH in the cartilage and synovial fluid of joints (Isaksson et al., 1991; Denko and Malemud, 2005), as well as in skeletal muscle (Kyle et al., 1981; Costa et al., 1993). Autocrine/paracrine GH has also been shown to be associated with muscle cell proliferation and myotube differentiation (Segard et al., 2003).
Extremes in GH action, both elevated and decreased, result in dramatic and distinct clinical conditions that have elucidated the role of this hormone on the musculoskeletal system. Acromegaly is a condition, usually resulting from a pituitary adenoma, that causes GH production in excess of normal physiological levels. The excess GH secretion leads to overproduction of IGF-1 and results in a multisystem disease characterized by somatic overgrowth and disfigurement, multiple comorbidities, and increased mortality (Melmed, 2009). Acromegaly is treated surgically to remove the tumor and/or pharmacologically with somatostatin analogues or the GH receptor antagonist, pegvisomant (Melmed, 2009). Decreased GH action takes two main clinical forms: GH deficiency (GHD), which has myriad causes, and Laron Syndrome (LS), which arises from GH receptor mutations (Laron and Werner, 2021). While the symptoms of GH deficiency vary due to etiology (Aguiar-Oliveira and Bartke, 2019), LS consistently causes short stature, improved glucose metabolism (Guevara-Aguirre et al., 2021) with respect to family members without LS, as well as a reduction in diagnosed malignancies observed in the control group (Guevara-Aguirre et al., 2011). Although GHD and LS may share many symptoms, their treatments differ. GHD is treated using GH replacement therapy with recombinant GH (Aguiar-Oliveira and Bartke, 2019), but in LS, GH replacement therapy is ineffective due to GH resistance, so recombinant IGF-1 is the only option to increase IGF-1 in these individuals (Guevara-Aguirre et al., 2021). All these conditions can result in skeletal and muscular changes that will be discussed briefly below.
Allowing more invasive measurements, various mouse lines have been developed (Table 1) to study the impact of GH action on the entire organism, select tissues or at specific timepoints. For example, bovine GH (bGH) transgenic mice (Knapp et al., 1994) have excess (superphysiological) GH action throughout their life, serving as a model for pediatric acromegaly or gigantism. As might be expected based on the known functions of GH, these mice are giant and lean. Despite their favorable body composition, bGH mice are insulin resistant (Dominici et al., 1999) due to the diabetogenic actions of GH and have a decreased lifespan (Knapp et al., 1994). Likewise, GHR knockout (GHRKO) mice are a model of LS. GHRKO mice have decreased body length and weight, increased insulin sensitivity, and markedly increased lifespan (Coschigano et al., 2003). As for GHD, mice with congenital GH deficiency (GH knockout or −/− mice) (List et al., 2019) and mice with adult GHD via GHR disruption starting at 6 months of age (6mGHRKO) (Duran-Ortiz et al., 2021b) or induced somatotroph destruction (Luque et al., 2011; Cordoba-Chacon et al., 2014; Poudel et al., 2021) have recently been developed. Many other mouse lines have also been created that provide insight into GH’s action although they lack clinical correlates. For example, GH signaling disruption in specific tissues such as muscle-specific (Mavalli et al., 2010; Vijayakumar et al., 2012; List et al., 2015), bone-specific (Liu et al., 2016) and liver-specific GHR knockouts have been characterized. This review will mainly summarize the musculoskeletal effects in bGH and GHRKO mice because they have each been more extensively studied.
TABLE 1. Summary of the musculoskeletal phenotypes of mouse models with altered GH action.
Important to the aging field, the levels of both GH and IGF-1 decline with advancing age in most mammalian species, referred to as somatopause. This age-related decline in both hormones, along with their potent anabolic effects in the musculoskeletal system, has sparked interest in the use of recombinant GH as an anti-aging drug (Lieberman and Hoffman, 1997). However, longevity data from both humans and mice challenge this notion. That is, mice with reduction or absence in GH action have a robust and reproducible increase in lifespan (Duran-Ortiz et al., 2021a), suggesting an advantage to somatopause on lifespan. While data from humans is insufficient to draw firm conclusions, individuals with LS have no decrease in lifespan and some cohorts of isolated GH deficiency (e.g. Brazilian Itabaianinha cohort) have attained extreme longevity despite representing a relative minor proportion of the population, suggesting that the findings in rodents are relevant to humans (Junnila et al., 2013). Despite the impact on lifespan, the benefits of GH supplementation on the aging musculoskeletal system have not been fully explored. Thus, this brief review will provide a summary of the complex effects of GH on the musculoskeletal system, focusing on extremes in GH action and on age-related conditions from clinical cohorts as well as in vivo data using animal models.
2 GH in Muscle
Skeletal muscle is a primary target for GH (and IGF-1) with growth-promoting effects. GH also has metabolic effects, with a well-documented ability to influence insulin-stimulated glucose uptake in skeletal muscle (Moller and Jorgensen, 2009). Below summarizes the impact of extremes in GH action (acromegaly and GH deficiency) on body composition and skeletal muscle structure and function from clinical studies as well as the role of GH in age-associated changes in skeletal muscle. Data from animal studies provides additional metabolic and physiological features of GH in muscle.
2.1 Clinical Data
2.1.1 Extremes in GH Action
2.1.1.1 Acromegaly
Patients with acromegaly have increases in lean mass and total body water (mainly extracellular water) (Bengtsson et al., 1989; Freda et al., 2009; Fuchtbauer et al., 2017). Despite the increase in lean mass, acromegaly is commonly believed to be associated with myopathy (characterized by muscle weakness and pain) and reduced muscle endurance (Mastaglia et al., 1970; Lopes et al., 2016). This acromegaly-associated myopathy can be a debilitating co-morbidity and is often considered a major contributor to the reduced quality of life reported for these patients (Miller et al., 2008). In terms of muscle function, cross-sectional studies have shown a decrease in hand grip strength, decreased peak torque, reduced maximal repetition in knee extension and flexion along with lateral instability (Lopes et al., 2016; Homem et al., 2017). However, a recent longitudinal study reports contrary results with a normal to modest increase in strength although confirmed the presence of reduced grip strength with active acromegaly (Fuchtbauer et al., 2017). While studies are limited, there are several structural changes in skeletal muscle with active acromegaly that are thought to contribute to the muscle dysfunction. That is, hypertrophy is noted in several studies but not all (Freda et al., 2009; Ozturk Gokce et al., 2020). As for muscle fiber type, most studies report hypertrophy of type I fibers but variable findings for type II fibers (Mastaglia et al., 1970; Nagulesparen et al., 1976; Khaleeli et al., 1984). An increase in intramuscular fat content has also been shown with active acromegaly (Reyes-Vidal et al., 2015). The excess GH associated with acromegaly is associated with insulin resistance and impaired insulin-stimulated glucose uptake in skeletal muscle (Moller et al., 1992; Moller and Jorgensen, 2009). Disease management improves but does not completely ameliorate the myopathy. For example, in the longitudinal study described above (Fuchtbauer et al., 2017), grip strength improves after disease remission but proximal muscle fatigue increases. Fat infiltration in the muscle also remains in controlled acromegaly (Martel-Duguech et al., 2021). Improvement in insulin resistance in muscle occurs with disease remission but varies depending on treatment modality (Dal et al., 2016).
2.1.1.2 GH Deficiency
Adults with GH deficiency (GHD) have decreased lean mass along with reduced isometric muscle strength (Jorgensen et al., 1989; Cuneo et al., 1991; Johannsson et al., 1997). Muscle endurance and isokinetic muscle strength are either reduced or in the lower range of normal (Cuneo et al., 1991; Johannsson et al., 1997). In general, GH replacement therapy of GHD increases lean body mass through both increasing skeletal muscle mass and tissue hydration (Jorgensen et al., 1989; Salomon et al., 1989; Cuneo et al., 1991; Rutherford et al., 1995; Elbornsson et al., 2013), as also confirmed in a comprehensive analysis of 51 clinical trials (Klefter and Feldt-Rasmussen, 2009). Of note, the increase in hydration of the muscle with GH therapy complicates the interpretation of most studies on GH therapy as methods used do not always differentiate between extracellular water and intracellular mass, which also confounds data presented above for acromegaly. GH replacement therapy in GHD for one year is associated with a 5–10% increase in muscle volume as assessed by either computed tomography or dual-energy X-ray absorptiometry scanning (Jorgensen et al., 1996). In a study that tracked patients for 10 years, GH treatment in patients with GHD confirms an increase muscle strength during the first years of treatment and partially protects from declines in muscle strength and neuromuscular function that occurs with aging (Gotherstrom et al., 2009).
As for other muscle properties, either no change in proportion of fiber types (Whitehead et al., 1989; Bottinelli et al., 1997) or data consistent with a larger proportion of type II fibers (Rutherford et al., 1995) has been reported for GHD, which normalize after GH therapy. Individuals with GHD may also have reduced capacity to restore intramyocellular lipids after aerobic exercise (Loher et al., 2018) although other studies do not show this trend (Christ et al., 2016). With respect to metabolism, untreated GHD is associated with reduced glycogen along with decreased insulin-stimulated glycogen synthase activity in skeletal muscle (Hew et al., 1996; Christopher et al., 1998). These defects persist after two years of GH treatment; that is, GH treatment of GHD leads to continued inhibition of insulin-stimulated glycogen synthase activity, accompanied by a reduced baseline glycogen content, low-to-normal glucose 6 phosphate levels, and high total intracellular glucose concentrations in skeletal muscle (Christopher et al., 1998), a unique combination to induce insulin resistance.
2.1.2 GH Action and Sarcopenia and Dynapenia
Sarcopenia and dynapenia are the age-associated loss of muscle mass and strength, respectively (Clark and Manini, 2008). As noted above, secretion of GH and IGF-1 decline with age such that low levels are detected in individuals over 60 years of age (Clemmons and Van Wyk, 1984; Zadik et al., 1985; Iranmanesh et al., 1991). These changes have sparked interest in using these hormones as therapy to combat age-related changes in muscle. Indeed, patients with sarcopenia have been reported to have lower GH and IGF-1 levels (Bian et al., 2020), with the severity of sarcopenia associated with reduced serum IGF-1 (Jarmusch et al., 2021). GH therapy in older adults has shown positive effects on body composition, with an increase in lean mass and a decrease in fat tissue (Taaffe et al., 1994; Papadakis et al., 1996; Franco et al., 2005). However, increase in muscle mass is not usually related to an improved physical ability or muscle strength (Taaffe et al., 1994; Papadakis et al., 1996; Lange et al., 2002) and has thrown doubt on its use as a strategy to combat sarcopenia or dynapenia. As noted before, the increases in lean mass may reflect increased fluid retention as opposed to lean tissue. Despite these discouraging results, some studies in elderly subjects that combine resistance training with GH therapy show improvements in muscle strength and a change in fiber types (Hennessey et al., 2001). Further recent studies suggest that a subset of patients with sarcopenia may be GH resistant (Ferrari et al., 2021), which may influence response to hormone therapy. Finally, recent data suggests the low IGF-1 in sarcopenia may be pathological to the muscle due to its potent effects on neurons (enhancing neuronal survival, neurite formation and outgrowth in motoneurons) (Jarmusch et al., 2021). Despite the integral role of the GH/IGF axis on muscle metabolism and hypertrophy, the use of GH or IGF-1 for its anti-aging properties remains controversial.
2.2 Mouse Data
2.2.1 Mice With Excess GH Action
GH’s role in muscle has been evaluated using bGH transgenic mice. bGH mice have increased muscle mass compared to controls, but muscle mass relative to body mass is unchanged (Schuenke et al., 2008). Muscle structure is changed, with a shift towards type I fibers, and an increased cross-sectional area across fiber types (Schuenke et al., 2008). Despite their increased muscle size, male bGH mice have similar grip strength to controls, indicating a less efficient muscle (Wolf et al., 1995). Increased muscle atrophy signals are also observed, with 5 month old bGH mice having increased circulating myostatin as well as increased MuRF1 expression in the gastrocnemius but not the soleus (Consitt et al., 2017). Skeletal muscle of bGH-transgenic mice has impaired insulin signaling at several levels, including 1) reduced insulin receptor abundance, 2) reduced insulin receptor tyrosine phosphorylation, 3) reduced IRS-1 tyrosine phosphorylation, and 4) defective activation of PI3K by insulin (that is, the association of IRS-1 with the p85 subunit is increased more 375% under basal conditions due to excess GH signaling which prevents its use for insulin signaling) (Dominici et al., 1999).
In vitro, cultured mouse limb myoblasts from wild type mice treated with GH show increases in myofiber size by promoting fusion of satellite-like myoblasts to nascent myotubes (Sotiropoulos et al., 2006). However, GH treatment of these limb myoblasts has no effect on size, proliferation, or differentiation of myoblast precursor cells indicating that GH plays a role in muscle cell fusion, rather than stimulating hyperplasia or hypertrophy of myoblast precursor cells (Sotiropoulos et al., 2006).
To delineate the effects of GH vs. endocrine IGF-1 action, several mouse lines that have a liver-specific ablation of the GHR have been generated, as most endocrine IGF-1 is produced in the liver in response to GH. These mice have intact GHR in all the tissues of the body, except for the liver; as a result, they present high GH, but low IGF-1 levels in the serum, having a form of extrahepatic acromegaly. These liver specific knockout animals have decreased lean mass but no change in quadriceps muscle mass and increased grip strength, indicating that high GH in the absence of high circulating IGF-1 may have a positive effect on muscle strength (List et al., 2014).
2.2.2 Mice With Reduced GH Action
Decreased GH action in muscle has been examined using GHRKO mice. While these mice have normal numbers of fibrils, myofiber size is reduced, resulting in an overall decrease in muscle mass (Sotiropoulos et al., 2006; Schuenke et al., 2008). Muscle fiber type has also been evaluated in these mice with mixed results. Sotiropoulos et al. (Sotiropoulos et al., 2006) report that soleus and tibialis anterior muscles from 2 month old GHRKO mice have a higher proportion of type II vs. type I fiber type compared to control mice. In contrast, Schuenke et al. (Schuenke et al., 2008) later reports no such change in fiber types from soleus, plantaris, and gastrocnemius at 4 months of age. These results suggest that the proportion of fiber types may depend on mouse age, strain, sex, and perhaps different muscle groups used. When muscle function is assessed using grip strength (normalized to body weight), 7 month old GHRKO mice show improvement compared to controls (Lozier et al., 2018). An aspect of the sex-specific effects of GH alterations has been further evaluated using orchidectomized GHRKO and WT mice and treatment with testosterone during late puberty (Venken et al., 2007). Testosterone treatment stimulates a similar increase in muscle mass in both GHRKO and WT mice indicating that androgens and GH stimulate muscle growth via distinct mechanisms (Venken et al., 2007). In terms of insulin metabolism, the muscles of GHRKO mice have increased insulin receptor expression, increased insulin stimulated p85 phosphorylation, increased insulin stimulated phosphorylated AKT1 and AKT2 phosphorylation, and increased total GLUT4 protein concentration (Bonkowski et al., 2009). Interestingly, two separate laboratories have demonstrated that when GHR is disrupted selectively in muscle, whole body insulin sensitivity is enhanced (Vijayakumar et al., 2012; List et al., 2015), with no reported change in muscle strength (List et al., 2015). In accordance with improved insulin sensitivity seen in muscle-specific GHRKO mice, these mice have a modest increase in lifespan (List et al., 2015).
Taken together, studies in humans and in numerous mouse models of altered GH action indicate that GH signaling is positively associated with muscle mass, but the increase in mass seen with GH excess does not confer increased muscle strength, possibly due to the altered structure of the muscle. Decreased GH signaling leads to decreased muscle mass, but the muscles appear to be relatively stronger despite inconsistent changes to muscle structure.
3 GH in Bone/Joints
GH (and IGF-1) also have robust anabolic effects on bone, stimulating osteoblast differentiation, linear bone growth, and increased BMD, among others. Mouse lines with altered GH/IGF-1 axis have been used to assess the role of GH on bone acquisition and metabolism. Overall, excess GH action results in augmented skeletal growth (D'Ercole, 1993), while reduction in the action of the GH/IGF-1 axis results in mice that, despite having normal body weight at birth, show a postnatal reduced skeletal acquisition compared to controls (Duran-Ortiz et al., 2021a). Below we summarize the skeletal phenotypes of mouse models with excess or reduced GH action.
3.1 Clinical Data
3.1.1 From Extremes in GH Action
3.1.1.1 Acromegaly
GH excess in acromegaly leads to increased bone turnover, as evidenced by increases in biochemical markers for both bone formation and resorption (Aloia et al., 1972; Lepszy et al., 1976; Halse et al., 1981; Halse and Gordeladze, 1981; de la Piedra et al., 1988; Ezzat et al., 1993; Kotzmann et al., 1993; Kayath and Vieira, 1997; Bolanowski et al., 2006). However, this increase in bone turnover does not correlate well with changes of bone mineral density (BMD) at the local level. Decreased BMD in lumbar spine and femoral neck has been reported in various studies (Aloia et al., 1972; Riggs et al., 1972; Halse et al., 1981; Seeman et al., 1982; Diamond et al., 1989; Kayath and Vieira, 1997; Lesse et al., 1998; Longobardi et al., 1998; Chiodini et al., 2001; Bolanowski et al., 2006), suggesting a higher rate of bone resorption versus formation. Consequently, a higher incidence of radiographical vertebral deformities and fractures has been reported in acromegaly (42.0%) compared to control subjects (3.8%) (Claessen et al., 2013). This suggests that acromegaly is linked to an increased risk of osteoporotic vertebral fracture. Whereas an opposite effect–increases in BMD–is observed in the forearm of patients with acromegaly (Seeman et al., 1982; Diamond et al., 1989). This can partially be explained by the differential responses of trabecular (such as in lumbar spine) and cortical bone (such as in forearm) to excess GH. Despite the strong anabolic effect of GH on bone, the net BMD gain/loss is likely a result of complex interactions of sex steroids with GH/IGF-1 axis, as reviewed elsewhere (Birzniece and Ho, 2017).
Joint manifestations are one of the most common clinical complications in patients with acromegaly. Either axial or peripheral arthropathy has been reported in more than 50% of patients (Layton et al., 1988). Typical radiographic osteoarthritic changes including joint space narrowing, osteophytosis, subchondral bony sclerosis, and cysts formation can be seen in some but not all patients with acromegaly (Layton et al., 1988; Colao et al., 2005). Some argue that those pathological changes might not be indicative of an osteoarthritis (OA) diagnosis as patients with acromegaly often times also have radiographic signs in the hand and spine joints unlike those commonly seen in OA (Tornero et al., 1990). Nevertheless, joint manifestation associated pain is one of the most common complications that greatly affects quality of life in long-standing acromegaly (Miller et al., 2008; Kropf et al., 2013).
3.1.1.2 GH Deficiency (GHD)
Decreased BMD has been consistently reported in patients with GH deficiency (GHD), either isolated or combined with other pituitary hormone deficiencies (Kaufman et al., 1992; Ohlsson et al., 1998; Wuster et al., 2001; Doga et al., 2005). The degree of bone loss is dependent on the sites, the duration and age of GHD onset, and the age of patients. Current evidence suggests that comparing with trabecular bone, cortical bone is more targeted by GHD (Johansson et al., 1992; Wuster et al., 2001). Consistently, the risk of nonvertebral fracture is increased approximately 3-fold in patients with GHD and the fractures are frequently localized to the radius (Johansson et al., 1992; Rosen et al., 1997; Wuster et al., 2001), a site rich in cortical bone. Additionally, patients with childhood-onset GHD are smaller and have a greater decrease of bone mass than patients with adult-onset GHD (Attanasio et al., 1997; Lissett and Shalet, 2002). This is thought to be due to missing effect from GH on reaching the peak bone mass during puberty (Bonjour et al., 1991). In contrast, the degree of bone loss in adult-onset GHD correlates with the age of patients and the duration and severity of the disease (Rosen et al., 1993; Holmes et al., 1994; Toogood et al., 1997; Colao et al., 1999; Murray et al., 2004; Fee and Bu, 2007). Conversely, when long-term recombinant GH therapy is used to treat patients with GHD, there is a resulting increase in BMD, with no change observed in trabecular bone score (Vanuga et al., 2021). Collectively, these studies demonstrated that GHD can contribute to bone loss and osteoporosis.
Not much is known about GHD on OA development. One comparative study has found that the prevalence of radiographic OA is lower in elderly patients with GHD than a normal population of elderly people (Bagge et al., 1993). Recently, a polymorphism of human GH receptor (GHR), the genomic deletion of exon 3 (d3GHR), was identified to be associated with increased growth velocity in children with GH deficiency (Urbanek et al., 1993; Dos Santos et al., 2004). This polymorphism enhances GH’s growth-promoting effects although GHR binding is not altered (Urbanek et al., 1993; Dos Santos et al., 2004). Interestingly, patients with d3GHR mutation have increased prevalence of OA, especially in hip joint, while both BMD and rate of (non)vertebral fractures are not significantly altered (Wassenaar et al., 2009; Claessen et al., 2014).
3.1.2 GH/IGF-1 Action and Age-Related Osteoporosis and Osteoarthritis
The level of GH and IGF1 decrease with aging (Clemmons and Van Wyk, 1984; Zadik et al., 1985; Iranmanesh et al., 1991), correlating with the increased risk of osteoporosis and fragility fracture in elderly population. A positive relationship between BMD and concentration of IGF-1 and IGF binding protein 3 (IGFBP-3) in serum is observed in healthy men (Johansson et al., 1994), and low serum IGF-1 level is associated with increased risk of hip and vertebral fractures (Ohlsson et al., 2011). However, the age-dependent decrease of GH and IGF-1 does not seem to always correlate with the reduction of BMD in humans. For example, in postmenopausal women with osteoporosis, serum IGF-1 does not differ from that in postmenopausal women without osteoporosis (Bennett et al., 1984). This suggests that aging associated skeletal homeostasis is likely a multifactorial process mediated by sex hormones, GH/IGF-1 axis, and others. Not surprisingly, the administration of GH or IGF-1 for treating osteoporosis in clinical trials has yielded mixed results. For example, in a randomized placebo-controlled trial in postmenopausal women with up to three years of follow-up, GH therapy results in 14% increase of BMD (Landin-Wilhelmsen et al., 2003), a result that was not reproduced in earlier trial (Saaf et al., 1999). The role of aging dependent decline of GH/IGF-1 on OA development has remained largely unknown, though one study showed that there was no direct link between either GH or IGF-1 serum level and OA (Lis, 2008).
3.2 Mouse Data
3.2.1 Mice With Excess GH Action
Mouse lines with excess GH, such as mice that overexpress human GHRH, human GH and bGH, show increased bone and body size (Wolf et al., 1991; D'Ercole, 1993; Jensen et al., 2021). Note that human GH binds to the prolactin receptor in addition to the GH receptor, while bGH only binds to the GH receptor. Therefore, bGH mice are a better model to study the specific effects of augmented GHR activation. bGH mice have increased bone length but compromised bone architecture and BMD with reduced trabecular bone volume fraction and thickness (Lim et al., 2015). Also, cortical tissue perimeter is increased in bGH mice, but cortical thickness is reduced. In lumbar vertebra, bGH mice show similar trabecular BMD but reduced trabecular thickness relative to controls while cortical BMD and thickness are significantly reduced in bGH mice. Importantly, at 5 months of age, bone turnover is increased in favor of bone resorption in at least bGH tibia (Lim et al., 2015). Pathohistological analysis of the knee joints from bGH mice at 6 months of age reveal that the mice have loss of articular cartilage zonal structure, presence of hypertrophic chondrocytes, and thickening of synovial lining tissue and pannus, suggesting osteoarthritic degeneration happens at an early age with GH overproduction (Eckstein et al., 2002; Eckstein et al., 2004). Similar cartilage degeneration is also seen in the hip joints of bGH mice (Munoz-Guerra et al., 2004).
The effects of GH action in bone are age- and sex-dependent in terms of BMD, cortical area, and bone minerals. For example, in bGH transgenic mice, only males have increased cortical cross-sectional area, yet females have increased trabecular density, femoral bone density, and trabecular bone volume fraction. However, the increased trabecular density in females was limited to younger ages between 6 and 12 weeks. Both sexes have decreased cortical density and mineralized tissue matrix density. It is apparent that in adulthood, excess GH action has a negative effect on bone structure (Eckstein et al., 2002; Eckstein et al., 2004). As noted previously, mice with a liver-specific GHR knockout have high circulating GH and low circulating IGF-1. Interestingly, different studies have found conflicting results for the body length of these mice, with two studies showing no difference (Yakar et al., 1999; Fan et al., 2009) and one study displaying significant decrease in body length (List et al., 2014) of the liver-specific GHR knockout mice compared to controls. These mice have impaired BMD with impaired cortical bone acquisition, microarchitecture, trabecular bone volume, and strength. With the exception of trabecular bone volume, these deficiencies are rescued when hepatic IGF-1 production is normalized by crossing these mice with hepatic IGF-1 transgenic mice (Liu et al., 2018). These results implicate IGF-1 as a major contributor to skeletal growth and structure.
As always when studying GH, it is difficult to tease out direct effects of GH from those mediated through IGF-1. In an in vitro experiment using osteoblasts from mice with an osteoblast-specific IGF-1R deletion, GH was shown to activate JAK2 and STAT5 normally. Other pathways had differing responses, as ERK activation by GH was normal in the absence of IGF-1R, while Akt activation was blunted.
3.2.2 Mice With Reduced GH Action
Germline reduction in GH action as seen in GHRKO mice results in mice with ∼50–60% decreased body size (List et al., 2019). Besides reduced longitudinal growth, 3 month old GHRKO mice also show decreased trabecular bone volume, as well as reduced cortical bone total cross-sectional area, bone area, cortical bone thickness, periosteal/endosteal circumference and reduced BMD and bone mineral content (BMC) (Sjogren et al., 2000). Furthermore, reduced skeletal growth in GHRKO mice has been associated with premature growth plate closure and reduced chondrocyte proliferation, bone turnover and periosteal bone apposition (Sims et al., 2000). To study the effects of reduced GH action postnatally, a mouse line with disrupted GHR at 6 months of age (6mGHRKO) was recently reported (Duran-Ortiz et al., 2021b; Dixit et al., 2021). Disrupting GHR globally at an adult age results in more slender bones, expansion of the marrow cavity, reduced osteocyte lacunar number, and increases in lacunar volume and loss of canalicular connectivity (Dixit et al., 2021). However, mineral/matrix ratio is not altered. Collectively, these studies show that germline and postnatal reduction of GH compromises morphology and development of the bones.
Moreover, one recent study examining an adult-onset isolated GH deficiency (AOiGHD) model found that reduction of GH during adulthood leads to increased cartilage degeneration and osteophyte formation in both male and female, while synovium thickening only in male (Poudel et al., 2021). Although not in mice, chronic GH/IGF-1 deficiency in a dwarf rat model (dw/dw) causes an increased severity of articular cartilage lesion of OA without formation of osteophytes and subchondral sclerosis. Interestingly, the cartilage lesion is ameliorated by a life-long repletion of GH (Ekenstedt et al., 2006). These results suggest a beneficial effect of reduced GH action on joint health, which is inconsistent from the aforementioned, pronounced OA phenotype in the bGH mice. This discrepancy is likely due to multiple factors including different genetic modified animal models, different species, and germline versus inducible deletion of GH.
To study the effects of GH action specifically on the bone, a mouse line with the GHR disrupted only in bone was generated, which results in bones that are resistant to GH but responsive to IGF-1. These mice, called dentin matrix protein (DMP)-1 GHRKO (DMP-GHRKO) mice (Liu et al., 2016), do not have any significant change in body weight, composition, and growth, although they show differences in bone acquisition. That is, DMP-GHRKO mice have decreased bone formation, mineral deposition rate, reduced cortical and trabecular areas, and increased and decreased number of osteoclasts and osteoblasts, respectively compared to controls (Liu et al., 2016). Altogether, these results show that germline reduction of GH action results in impaired skeletal growth and decreased bone mineral density.
4 Experimental Variant of Human GH
While this review has focused on “GH”, it is important to remember that the human GH gene family is made up of five genes that share similar structure. These five genes include, GH-N (the main focus of this review), GH-V (also called placental GH), chorionic somatomammotropin hormone 1 (also called placental lactogen 1), chorionic somatomammotropin hormone 2 (also called placental lactogen 2), and a pseudogene called chorionic somatomammotropin-like hormone. While GH-N is produced mainly in the pituitary, all other members of the GH gene family are produced in the placenta. GH-V is 93% identical to GH-N at the amino acid level, and the 22K isoform, which is the most abundant isoform of GH-V, has been shown to promote growth and mediate maternal insulin resistance during pregnancy (Miller and Eberhardt, 1983; Solomon et al., 2006). Another isoform, a 20K GH-V isoform, is expressed at low levels (Boguszewski et al., 1998); however, two separate laboratories indicate that the 20K GH-V isoform has potent effects when given at therapeutic levels. Specifically, 20K GH-V stimulates IGF-1, increases longitudinal bone growth, increases muscle mass, and reduces fat mass when injected into mice and rats (Vickers et al., 2009; List et al., 2020). Importantly, while 20K GH-V appears to have full anabolic activity, it lacks diabetogenic and lactogenic activities found in human GH-N (Vickers et al., 2009; List et al., 2020). The clinical implications of a GH that lacks diabetogenic and lactogenic activities is attractive since both of these activities are generally associated with negative health consequences. While still very preliminary and only in rodents, these data suggest that 20K GH-V may represent improvements to current GH therapies for bone or muscle-related maladies.
5 Conclusion
Growth hormone has its most notable effects on the musculoskeletal system, as these effects lend GH its name. Overall, GH acts directly and indirectly through IGF-1 to increase bone and muscle mass, but the increase in mass does not necessarily result in increased strength in either tissue. The lack of increased strength may be explained by changes in fiber type in muscle and decreased BMD in some types of bone. GH deficiency causes decreased bone and muscle mass and strength, and GH treatment of GHD increases bone and muscle mass and muscle strength. Animal models of increased (bGH mice) and decreased (GHRKO mice) GH action mirror the results seen in their respective clinical populations.
Many questions remain unanswered. First, what is the role of GH versus IGF-1? A key aspect of GH action is the distinction between its direct and IGF-1 mediated effects, but in clinical populations (with the exception of rare conditions like LS), high circulating GH is coupled with high circulating IGF-1 or vice versa. A mouse model that decouples high GH from high IGF-1 (Liver specific GHR knockout mice, which have high GH but low IGF-1) shows a distinct muscle phenotype with increased grip strength. Likewise, IGF-1 transgenic mice, with high IGF-1 but low GH, have increased body weight but no increase in skeletal growth (Mathews et al., 1988). A previous review has summarized the distinct and overlapping effects of GH and IGF-1 on bone (Yakar and Isaksson, 2016), highlighting the complexity of this issue.
Second, does GH have potential utility for treating age-related conditions? GH and IGF-1 have significant anabolic effects in both skeletal muscle and bone, making them of high interest as an anti-aging therapy for disorders in these tissues (Bartke, 2019). To date, data are sparse for the specific benefits of GH therapy for both sarcopenia and OA and inconsistent for other conditions, such as osteoporosis. Further, GH resistance, treatment regimen/duration, age of treatment and sex are all important variables that have not been appropriately assessed. However, there are negative metabolic consequences of using GH in older adults. That is, as GH promotes insulin resistance, promoting diabetes. Further, both GH and IGF-1 appear to contribute to the development, progression, therapy resistance and metastases of multiple human cancers expressing GHRs (Basu and Kopchick, 2019). Controlled exposure to GH or the use of GH variants, which have the anabolic effect on bone and muscle but lack some of the diabetogenic action (List et al., 2020), are possible modes of treatment. Thus, the intricate links between GH, the musculoskeletal system, metabolism, and lifespan have room for further investigation.
Author Contributions
JY, SZ, EL, SD, YS, and DB wrote sections of the manuscript. All authors contributed to manuscript revision, read, and approved the submitted version.
Funding
This work was supported in part by NIH grant #AG059779, Ohio University Heritage College of Osteopathic Medicine, The Diabetes Institute at Ohio University, and the State of Ohio’s Eminent Scholar Program that includes a gift from Milton and Lawrence Goll.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Aguiar-Oliveira M. H., Bartke A. (2019). Growth Hormone Deficiency: Health and Longevity. Endocr. Rev. 40 (2), 575–601. doi:10.1210/er.2018-00216
Aloia J. F., Roginsky M. S., Jowsey J., Dombrowski C. S., Shukla K. K., Cohn S. H. (1972). Skeletal Metabolism and Body Composition in Acromegaly. J. Clin. Endocrinol. Metabolism 35 (4), 543–551. doi:10.1210/jcem-35-4-543
Attanasio A. F., Lamberts S. W., Matranga A. M., Birkett M. A., Bates P. C., Valk N. K., et al. (1997). Adult Growth Hormone (Gh)-Deficient Patients Demonstrate Heterogeneity Between Childhood Onset and Adult Onset Before and During Human Gh Treatment. Adult Growth Hormone Deficiency Study Group. J. Clin. Endocrinol. Metabolism 82 (1), 82–88. doi:10.1210/jcem.82.1.3643
Bagge E., Edén S., Rosén T., Bengtsson B.-Å. (1993). The Prevalence of Radiographic Osteoarthritis Is Low in Elderly Patients with Growth Hormone Deficiency. Acta Endocrinol. (Copenh) 129 (4), 296–300. doi:10.1530/acta.0.1290296
Bartke A. (2019). Growth Hormone and Aging: Updated Review. World J. Mens. Health 37 (1), 19–30. doi:10.5534/wjmh.180018
Basu R., Kopchick J. J. (2019). The Effects of Growth Hormone on Therapy Resistance in Cancer. Cancer Drug Resist 2, 827–846. doi:10.20517/cdr.2019.27
Bengtsson B.-Å., Brummer R.-J. M., Eden S., Bosaeus I. (1989). Body Composition in Acromegaly. Clin. Endocrinol. 30 (2), 121–130. doi:10.1111/j.1365-2265.1989.tb03733.x
Bennett A. E., Wahner H. W., Riggs B. L., Hintz R. L. (1984). Insulin-Like Growth Factors I and II: Aging and Bone Density in Women*. J. Clin. Endocrinol. Metabolism 59 (4), 701–704. doi:10.1210/jcem-59-4-701
Bian A., Ma Y., Zhou X., Guo Y., Wang W., Zhang Y., et al. (2020). Association between Sarcopenia and Levels of Growth Hormone and Insulin-like Growth Factor-1 in the Elderly. BMC Musculoskelet. Disord. 21 (1), 214. doi:10.1186/s12891-020-03236-y
Birzniece V., Ho K. K. Y. (2017). Sex Steroids and the GH axis: Implications for the Management of Hypopituitarism. Best Pract. Res. Clin. Endocrinol. Metabolism 31 (1), 59–69. doi:10.1016/j.beem.2017.03.003
Boguszewski C. L., Svensson P.-A., Jansson T., Clark R., Carlsson L. M. S., Carlsson B. (1998). Cloning of Two Novel Growth Hormone Transcripts Expressed in Human Placenta1. J. Clin. Endocrinol. Metabolism 83 (8), 2878–2885. doi:10.1210/jcem.83.8.5017
Bolanowski M., Daroszewski J., Mędraś M., Zadrożna-Śliwka B. (2005). Bone Mineral Density and Turnover in Patients with Acromegaly in Relation to Sex, Disease Activity, and Gonadal Function. J. Bone Min. Metab. 24 (1), 72–78. doi:10.1007/s00774-005-0649-9
Bonjour J.-P., Theintz G., Buchs B., Slosman D., Rizzoli R. (1991). Critical Years and Stages of Puberty for Spinal and Femoral Bone Mass Accumulation during Adolescence. J. Clin. Endocrinol. Metabolism 73 (3), 555–563. doi:10.1210/jcem-73-3-555
Bonkowski M. S., Dominici F. P., Arum O., Rocha J. S., Al Regaiey K. A., Westbrook R., et al. (2009). Disruption of Growth Hormone Receptor Prevents Calorie Restriction from Improving Insulin Action and Longevity. Plos One 4 (2), e4567. doi:10.1371/journal.pone.0004567
Bottinelli R., Narici M., Pellegrino M. A., Kayser B., Canepari M., Faglia G., et al. (1997). Contractile Properties and Fiber Type Distribution of Quadriceps Muscles in Adults with Childhood-Onset Growth Hormone Deficiency. J. Clin. Endocrinol. Metabolism 82 (12), 4133–4138. doi:10.1210/jcem.82.12.4426
Brooks A. J., Waters M. J. (2010). The Growth Hormone Receptor: Mechanism of Activation and Clinical Implications. Nat. Rev. Endocrinol. 6 (9), 515–525. doi:10.1038/nrendo.2010.123
Caputo M., Pigni S., Agosti E., Daffara T., Ferrero A., Filigheddu N., et al. (2021). Regulation of GH and GH Signaling by Nutrients. Cells 10 (6), 1376. doi:10.3390/cells10061376
Chiodini I., Trischitta V., Carnevale V., Liuzzi A., Scillitani A. (2001). Bone Mineral Density in Acromegaly: Does Growth Hormone Excess Protect against Osteoporosis? J. Endocrinol. Invest 24 (4), 288–291. doi:10.1007/BF03343859
Christ E. R., Egger A., Allemann S., Buehler T., Kreis R., Boesch C. (2016). Effects of Aerobic Exercise on Ectopic Lipids in Patients with Growth Hormone Deficiency before and after Growth Hormone Replacement Therapy. Sci. Rep. 6, 19310. doi:10.1038/srep19310
Christopher M., Hew F. L., Oakley M., Rantzau C., Alford F. (1998). Defects of Insulin Action and Skeletal Muscle Glucose Metabolism in Growth Hormone-Deficient Adults Persist after 24 Months of Recombinant Human Growth Hormone Therapy1. J. Clin. Endocrinol. Metabolism 83 (5), 1668–1681. doi:10.1210/jcem.83.5.4836
Claessen K. M. J. A., Kloppenburg M., Kroon H. M., Bijsterbosch J., Pereira A. M., Romijn J. A., et al. (2014). Relationship Between the Functional Exon 3 Deleted Growth Hormone Receptor Polymorphism and Symptomatic Osteoarthritis in Women. Ann. Rheum. Dis. 73 (2), 433–436. doi:10.1136/annrheumdis-2012-202713
Claessen K. M. J. A., Kroon H. M., Pereira A. M., Appelman-Dijkstra N. M., Verstegen M. J., Kloppenburg M., et al. (2013). Progression of Vertebral Fractures Despite Long-Term Biochemical Control of Acromegaly: a Prospective Follow-Up Study. J. Clin. Endocrinol. Metab. 98 (12), 4808–4815. doi:10.1210/jc.2013-2695
Clark B. C., Manini T. M. (2008). Sarcopenia != Dynapenia. Journals Gerontology Ser. A Biol. Sci. Med. Sci. 63 (8), 829–834. doi:10.1093/gerona/63.8.829
Clemmons D. R., Van Wyk J. J. (1984). 6 Factors Controlling Blood Concentration of Somatomedin C. Clin. Endocrinol. Metabolism 13 (1), 113–143. doi:10.1016/s0300-595x(84)80011-0
Colao A., Pivonello R., Scarpa R., Vallone G., Ruosi C., Lombardi G. (2005). The Acromegalic Arthropathy. J. Endocrinol. Invest 28 (8 Suppl. l), 24–31.
Colao A., Di Somma C., Pivonello R., Loche S., Aimaretti G., Cerbone G., et al. (1999). Bone Loss Is Correlated to the Severity of Growth Hormone Deficiency in Adult Patients with Hypopituitarism1. J. Clin. Endocrinol. Metabolism 84 (6), 1919–1924. doi:10.1210/jcem.84.6.5742
Consitt L. A., Saneda A., Saxena G., List E. O., Kopchick J. J. (2017). Mice Overexpressing Growth Hormone Exhibit Increased Skeletal Muscle Myostatin and MuRF1 with Attenuation of Muscle Mass. Skelet. Muscle 7 (1), 17. doi:10.1186/s13395-017-0133-y
Cordoba-Chacon J., Gahete M. D., Pokala N. K., Geldermann D., Alba M., Salvatori R., et al. (2014). Long- But Not Short-Term Adult-Onset, Isolated GH Deficiency in Male Mice Leads to Deterioration of β-Cell Function, Which Cannot Be Accounted for by Changes in β-Cell Mass. Endocrinology 155 (3), 726–735. doi:10.1210/en.2013-1825
Coschigano K. T., Holland A. N., Riders M. E., List E. O., Flyvbjerg A., Kopchick J. J. (2003). Deletion, but Not Antagonism, of the Mouse Growth Hormone Receptor Results in Severely Decreased Body Weights, Insulin, and Insulin-like Growth Factor I Levels and Increased Life Span. Endocrinology 144 (9), 3799–3810. doi:10.1210/en.2003-0374
Costa A., Zoppetti G., Benedetto C., Bertino E., Marozio L., Fabris C., et al. (1993). Immunolike Growth Hormone Substance in Tissues from Human Embryos/fetuses and Adults. J. Endocrinol. Invest 16 (8), 625–633. doi:10.1007/BF03347684
Cuneo R. C., Salomon F., Wiles C. M., Hesp R., Sonksen P. H. (19911985). Growth Hormone Treatment in Growth Hormone-Deficient Adults. I. Effects on Muscle Mass and Strength. J. Appl. Physiology 70 (2), 688–694. doi:10.1152/jappl.1991.70.2.688
D'Ercole A. J. (1993). Expression of Insulin-like Growth Factor-I in Transgenic Mice. Ann. N. Y. Acad. Sci. 692, 149–160. doi:10.1111/j.1749-6632.1993.tb26213.x
Dal J., Høyer K. L., Pedersen S. B., Magnusson N. E., Bjerring P., Frystyk J., et al. (2016). Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment. J. Clin. Endocrinol. Metabolism 101 (10), 3716–3723. doi:10.1210/jc.2016-1806
de la Piedra C., Carbó E., Larrañaga J., Castro N., Horcajada C., Rapado A., et al. (1988). Correlation Among Plasma Osteocalcin, Growth Hormone, and Somatomedin C in Acromegaly. Calcif. Tissue Int. 43 (1), 44–45. doi:10.1007/BF02555167
Denko C. W., Malemud C. J. (2005). Role of the Growth Hormone/insulin-like Growth Factor-1 Paracrine axis in Rheumatic Diseases. Seminars Arthritis Rheumatism 35 (1), 24–34. doi:10.1016/j.semarthrit.2005.03.001
Diamond T., Nery L., Posen S. (1989). Spinal and Peripheral Bone Mineral Densities in Acromegaly: the Effects of Excess Growth Hormone and Hypogonadism. Ann. Intern Med. 111 (7), 567–573. doi:10.7326/0003-4819-111-7-567
Dixit M., Duran‐Ortiz S., Yildirim G., Poudel S. B., Louis L. D., Bartke A., et al. (2021). Induction of Somatopause in Adult Mice Compromises Bone Morphology and Exacerbates Bone Loss during Aging. Aging Cell 20 (12), e13505. doi:10.1111/acel.13505
Doga M., Bonadonna S., Gola M., Mazziotti G., Nuzzo M., Giustina A. (2005). GH Deficiency in the Adult and Bone. J. Endocrinol. Invest 28 (8 Suppl. l), 18–23.
Dominici F. P., Cifone D., Bartke A., Turyn D. (1999). Alterations in the Early Steps of the Insulin-Signaling System in Skeletal Muscle of GH-Transgenic Mice. Am. J. Physiology-Endocrinology Metabolism 277 (3), E447–E454. doi:10.1152/ajpendo.1999.277.3.E447
Dos Santos C., Essioux L., Teinturier C., Tauber M., Goffin V., Bougnères P. (2004). A Common Polymorphism of the Growth Hormone Receptor Is Associated with Increased Responsiveness to Growth Hormone. Nat. Genet. 36 (7), 720–724. doi:10.1038/ng1379
Duran-Ortiz S., List E. O., Basu R., Kopchick J. J. (2021a). Extending Lifespan by Modulating the Growth Hormone/Insulin-Like Growth Factor-1 axis: Coming of Age. Pituitary 24 (3), 438–456. doi:10.1007/s11102-020-01117-0
Duran‐Ortiz S., List E. O., Ikeno Y., Young J., Basu R., Bell S., et al. (2021b). Growth Hormone Receptor Gene Disruption in Mature‐adult Mice Improves Male Insulin Sensitivity and Extends Female Lifespan. Aging Cell 20 (12), e13506. doi:10.1111/acel.13506
Eckstein F., Lochmüller E.-M., Koller B., Wehr U., Weusten A., Rambeck W., et al. (2002). Body Composition, Bone Mass and Microstructural Analysis in GH-Transgenic Mice Reveals that Skeletal Changes Are Specific to Bone Compartment and Gender. Growth Hormone IGF Res. 12 (2), 116–125. doi:10.1054/ghir.2002.0272
Eckstein F., Weusten A., Schmidt C., Wehr U., Wanke R., Rambeck W., et al. (2004). Longitudinal In Vivo Effects of Growth Hormone Overexpression on Bone in Transgenic Mice. J. Bone Min. Res. 19 (5), 802–810. doi:10.1359/JBMR.040308
Ekenstedt K. J., Sonntag W. E., Loeser R. F., Lindgren B. R., Carlson C. S. (2006). Effects of Chronic Growth Hormone and Insulin-like Growth Factor 1 Deficiency on Osteoarthritis Severity in Rat Knee Joints. Arthritis Rheum. 54 (12), 3850–3858. doi:10.1002/art.22254
Elbornsson M., Götherström G., Bosæus I., Bengtsson B.-Å., Johannsson G., Svensson J. (2013). Fifteen Years of GH Replacement Improves Body Composition and Cardiovascular Risk Factors. Eur. J. Endocrinol. 168 (5), 745–753. doi:10.1530/EJE-12-1083
Ezzat S., Melmed S., Endres D., Eyre D. R., Singer F. R. (1993). Biochemical Assessment of Bone Formation and Resorption in Acromegaly. J. Clin. Endocrinol. Metabolism 76 (6), 1452–1457. doi:10.1210/jcem.76.6.8501150
Fan Y., Menon R. K., Cohen P., Hwang D., Clemens T., DiGirolamo D. J., et al. (2009). Liver-specific Deletion of the Growth Hormone Receptor Reveals Essential Role of Growth Hormone Signaling in Hepatic Lipid Metabolism. J. Biol. Chem. 284 (30), 19937–19944. doi:10.1074/jbc.M109.014308
Fee E., Bu L. (2007). Models of Public Health Education: Choices for the Future? Bull. World Health Organ 85 (12), 977–979. doi:10.2471/blt.07.044883
Ferrari U., Schmidmaier R., Jung T., Reincke M., Martini S., Schoser B., et al. (2021). IGF-I/IGFBP3/ALS Deficiency in Sarcopenia: Low GHBP Suggests GH Resistance in a Subgroup of Geriatric Patients. J. Clin. Endocrinol. Metab. 106 (4), 1698–1707. doi:10.1210/clinem/dgaa972
Franco C., Brandberg J., Lönn L., Andersson B., Bengtsson B.-Å., Johannsson G. (2005). Growth Hormone Treatment Reduces Abdominal Visceral Fat in Postmenopausal Women with Abdominal Obesity: a 12-month Placebo-Controlled Trial. J. Clin. Endocrinol. Metabolism 90 (3), 1466–1474. doi:10.1210/jc.2004-1657
Freda P. U., Shen W., Reyes-Vidal C. M., Geer E. B., Arias-Mendoza F., Gallagher D., et al. (2009). Skeletal Muscle Mass in Acromegaly Assessed by Magnetic Resonance Imaging and Dual-Photon X-Ray Absorptiometry. J. Clin. Endocrinol. Metab. 94 (8), 2880–2886. doi:10.1210/jc.2009-0026
Füchtbauer L., Olsson D. S., Bengtsson B.-Å., Norrman L.-L., Sunnerhagen K. S., Johannsson G. (2017). Muscle Strength in Patients with Acromegaly at Diagnosis and during Long-Term Follow-Up. Eur. J. Endocrinol. 177 (2), 217–226. doi:10.1530/EJE-17-0120
Götherström G., Elbornsson M., Stibrant-Sunnerhagen K., Bengtsson B.-A., Johannsson G., Svensson J. (2009). Ten Years of Growth Hormone (GH) Replacement Normalizes Muscle Strength in GH-Deficient Adults. J. Clin. Endocrinol. Metab. 94 (3), 809–816. doi:10.1210/jc.2008-1538
Guevara-Aguirre J., Balasubramanian P., Guevara-Aguirre M., Wei M., Madia F., Cheng C.-W., et al. (2011). Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-aging Signaling, Cancer, and Diabetes in Humans. Sci. Transl. Med. 3 (70). 70ra13. doi:10.1126/scitranslmed.3001845
Guevara-Aguirre J., Bautista C., Torres C., Peña G., Guevara C., Palacios C., et al. (2021). Insights from the Clinical Phenotype of Subjects with Laron Syndrome in Ecuador. Rev. Endocr. Metab. Disord. 22 (1), 59–70. doi:10.1007/s11154-020-09602-4
Halse J., Gordeladze J. O. (1981). Total and Non-dialyzable Urinary Hydroxyproline in Acromegalics and Control Subjects. Acta Endocrinol. (Copenh) 96 (4), 451–457. doi:10.1530/acta.0.0960451
Halse J., Melsen F., Mosekilde L. (1981). Iliac Crest Bone Mass and Remodelling in Acromegaly. Acta Endocrinol. (Copenh) 97 (1), 18–22. doi:10.1530/acta.0.0970018
Harvey S. (2010). Extrapituitary Growth Hormone. Endocr 38 (3), 335–359. doi:10.1007/s12020-010-9403-8
Hellström A., Ley D., Hallberg B., Löfqvist C., Hansen-Pupp I., Ramenghi L. A., et al. (2018). IGF-1 as a Drug for Preterm Infants: A Step-Wise Clinical Development. Curr. Pharm. Des 23 (38), 5964–5970. doi:10.2174/1381612823666171002114545
Hennessey J. V., Chromiak J. A., DellaVentura S., Reinert S. E., Puhl J., Kiel D. P., et al. (2001). Growth Hormone Administration and Exercise Effects on Muscle Fiber Type and Diameter in Moderately Frail Older People. J. Am. Geriatr. Soc. 49 (7), 852–858. doi:10.1046/j.1532-5415.2001.49173.x
Hew F. L., Koschmann M., Christopher M., Rantzau C., Vaag A., Ward G., et al. (1996). Insulin Resistance in Growth Hormone-Deficient Adults: Defects in Glucose Utilization and Glycogen Synthase Activity. J. Clin. Endocrinol. Metabolism 81 (2), 555–564. doi:10.1210/jcem.81.2.8636267
Holmes S. J., Economou G., Whitehouse R. W., Adams J. E., Shalet S. M. (1994). Reduced Bone Mineral Density in Patients with Adult Onset Growth Hormone Deficiency. J. Clin. Endocrinol. Metabolism 78 (3), 669–674. doi:10.1210/jcem.78.3.8126140
Homem T. S., Guimarães F. S., Soares M. S., Kasuki L., Gadelha M. R., Lopes A. J. (2017). Balance Control and Peripheral Muscle Function in Aging: A Comparison Between Individuals with Acromegaly and Healthy Subjects. J. Aging Phys. Act. 25 (2), 218–227. doi:10.1123/japa.2016-0100
Houssay B. A., Biasotti A. (1931). The Hypophysis, Carbohydrate Metabolism and Diabetes. Endocrinology 15 (6), 511–523. doi:10.1210/endo-15-6-511
Iranmanesh A., Lizarralde G., Veldhuis J. D. (1991). Age and Relative Adiposity Are Specific Negative Determinants of the Frequency and Amplitude of Growth Hormone (GH) Secretory Bursts and the Half-Life of Endogenous GH in Healthy Men*. J. Clin. Endocrinol. Metabolism 73 (5), 1081–1088. doi:10.1210/jcem-73-5-1081
Isaksson O. G. P., Ohlsson C., Nilsson A., Isgaard J. r., Lindahl A. (1991). Regulation of Cartilage Growth by Growth Hormone and Insulin-like Growth Factor I. Pediatr. Nephrol. 5 (4), 451–453. doi:10.1007/BF01453680
Jarmusch S., Baber L., Bidlingmaier M., Ferrari U., Hofmeister F., Hintze S., et al. (2021). Influence of IGF-I Serum Concentration on Muscular Regeneration Capacity in Patients with Sarcopenia. BMC Musculoskelet. Disord. 22 (1), 807. doi:10.1186/s12891-021-04699-3
Jensen E. A., Young J. A., Kuhn J., Onusko M., Busken J., List E. O., et al. (2021). Growth Hormone Alters Gross Anatomy and Morphology of the Small and Large Intestines in Age- and Sex-dependent Manners. Pituitary 25, 116–130. doi:10.1007/s11102-021-01179-8
Johannsson G., Grimby G., Sunnerhagen K. S., Bengtsson B.-A. (1997). Two Years of Growth Hormone (GH) Treatment Increase Isometric and Isokinetic Muscle Strength in GH-Deficient Adults*. J. Clin. Endocrinol. Metab. 82 (9), 2877–2884. doi:10.1210/jcem.82.9.4204
Johansson A. G., Burman P., Westermark K., Ljunghall S. (1992). The Bone Mineral Density in Acquired Growth Hormone Deficiency Correlates with Circulating Levels of Insulin-like Growth Factor I. J. Intern Med. 232 (5), 447–452. doi:10.1111/j.1365-2796.1992.tb00613.x
Johansson A. G., Forslund A., Hambraeus L., Blum W. F., Ljunghall S. (1994). Growth Hormone-dependent Insulin-like Growth Factor Binding Protein Is a Major Determinant of Bone Mineral Density in Healthy Men. J. Bone Min. Res. 9 (6), 915–921. doi:10.1002/jbmr.5650090617
Jørgensen J. O., Pedersen S. A., Thuesen L., Jørgensen J., Ingemann-Hansen T., Skakkebaek N. E., et al. (1989). Beneficial Effects of Growth Hormone Treatment in GH-Deficient Adults. Lancet 1 (8649), 1221–1225. doi:10.1016/s0140-6736(89)92328-3
Jørgensen J. O. L., Vahl N., Hansen T. B., Thuesen L., Hagen C., Christiansen J. S. (1996). Growth Hormone versus Placebo Treatment for One Year in Growth Hormone Deficient Adults: Increase in Exercise Capacity and Normalization of Body Composition. Clin. Endocrinol. 45 (6), 681–688. doi:10.1046/j.1365-2265.1996.8720883.x
Junnila R. K., List E. O., Berryman D. E., Murrey J. W., Kopchick J. J. (2013). The GH/IGF-1 axis in Ageing and Longevity. Nat. Rev. Endocrinol. 9 (6), 366–376. doi:10.1038/nrendo.2013.67
Kaufman J. M., Taelman P., Vermeulen A., Vandeweghe M. (1992). Bone Mineral Status in Growth Hormone-Deficient Males with Isolated and Multiple Pituitary Deficiencies of Childhood Onset. J. Clin. Endocrinol. Metabolism 74 (1), 118–123. doi:10.1210/jcem.74.1.1727808
Kayath M. J., Vieira J. G. H. (1997). Osteopenia Occurs in a Minority of Patients with Acromegaly and Is Predominant in the Spine. Osteoporos. Int. 7 (3), 226–230. doi:10.1007/BF01622293
Khaleeli A. A., Levy R. D., Edwards R. H., McPhail G., Mills K. R., Round J. M., et al. (1984). The Neuromuscular Features of Acromegaly: a Clinical and Pathological Study. J. Neurology, Neurosurg. Psychiatry 47 (9), 1009–1015. doi:10.1136/jnnp.47.9.1009
Klefter O., Feldt-Rasmussen U. (2009). Is Increase in Bone Mineral Content Caused by Increase in Skeletal Muscle Mass/strength in Adult Patients with GH-Treated GH Deficiency? A Systematic Literature Analysis. Eur. J. Endocrinol. 161 (2), 213–221. doi:10.1530/EJE-09-0160
Knapp J. R., Chen W. Y., Turner N. D., Byers F. M., Kopchick J. J. (1994). Growth Patterns and Body Composition of Transgenic Mice Expressing Mutated Bovine Somatotropin Genes1. J. Anim. Sci. 72 (11), 2812–2819. doi:10.2527/1994.72112812x
Kopchick J. J., Andry J. M. (2000). Growth Hormone (GH), GH Receptor, and Signal Transduction. Mol. Genet. Metabolism 71 (1-2), 293–314. doi:10.1006/mgme.2000.3068
Kotzmann H., Bernecker P., Hübsch P., Pietschmann P., Woloszczuk W., Svoboda T., et al. (1993). Bone Mineral Density and Parameters of Bone Metabolism in Patients with Acromegaly. J. Bone Min. Res. 8 (4), 459–465. doi:10.1002/jbmr.5650080410
Kropf L. L., Madeira M., Neto L. V., Roberto Gadelha M., de Farias M. L. F. (2013). Functional Evaluation of the Joints in Acromegalic Patients and Associated Factors. Clin. Rheumatol. 32 (7), 991–998. doi:10.1007/s10067-013-2219-1
Kyle C. V., Evans M. C., Odell W. D. (1981). Growth Hormone-like Material in Normal Human Tissues. J. Clin. Endocrinol. Metabolism 53 (6), 1138–1144. doi:10.1210/jcem-53-6-1138
Landin-Wilhelmsen K., Nilsson A., Bosaeus I., Bengtsson B.-Å. (2003). Growth Hormone Increases Bone Mineral Content in Postmenopausal Osteoporosis: a Randomized Placebo-Controlled Trial. J. Bone Min. Res. 18 (3), 393–405. doi:10.1359/jbmr.2003.18.3.393
Lange K. H. W., Andersen J. L., Beyer N., Isaksson F., Larsson B., Rasmussen M. H., et al. (2002). GH Administration Changes Myosin Heavy Chain Isoforms in Skeletal Muscle but Does Not Augment Muscle Strength or Hypertrophy, Either Alone or Combined with Resistance Exercise Training in Healthy Elderly Men. J. Clin. Endocrinol. Metabolism 87 (2), 513–523. doi:10.1210/jcem.87.2.8206
Laron Z., Werner H. (2021). Laron Syndrome - A Historical Perspective. Rev. Endocr. Metab. Disord. 22 (1), 31–41. doi:10.1007/s11154-020-09595-0
Layton M. W., Fudman E. J., Barkan A., Braunstein E. M., Fox I. H. (1988). Acromegalic Arthropathy. Arthritis & Rheumatism 31 (8), 1022–1027. doi:10.1002/art.1780310813
Lepszy H., Irmscher K., Wiegelmann W., Solbach H., Krüskemper H. (1976). Die Harnausscheidung des Hydroxyprolins bei Akromegalie. Dtsch. Med. Wochenschr 101 (22), 857–861. doi:10.1055/s-0028-1104184
Lesse G. P., Fraser W. D., Farquharson R., Hipkin L., Vora J. P. (1998). Gonadal Status Is an Important Determinant of Bone Density in Acromegaly. Clin. Endocrinol. 48 (1), 59–65. doi:10.1046/j.1365-2265.1998.00349.x
Lieberman S. A., Hoffman A. R. (1997). The Somatopause: Should Growth Hormone Deficiency in Older People Be Treated? Clin. Geriatric Med. 13 (4), 671–684. doi:10.1016/s0749-0690(18)30143-5
Lim S. V., Marenzana M., Hopkinson M., List E. O., Kopchick J. J., Pereira M., et al. (2015). Excessive Growth Hormone Expression in Male GH Transgenic Mice Adversely Alters Bone Architecture and Mechanical Strength. Endocrinology 156 (4), 1362–1371. doi:10.1210/en.2014-1572
Lis K. (2008). Insulin-like Growth Factor 1 (IGF-1) and Growth Hormone (hGH) as the Markers of Osteoarthritis. Chir. Narzadow Ruchu Ortop. Pol. 73 (1), 49–52.
Lissett C. A., Shalet S. M. (2002). Childhood-onset Growth Hormone (GH) Deficiency in Adult Life. Best Pract. Res. Clin. Endocrinol. Metabolism 16 (2), 209–224. doi:10.1053/beem.2002.0196
List E. O., Berryman D. E., Basu R., Buchman M., Funk K., Kulkarni P., et al. (2020). The Effects of 20-kDa Human Placental GH in Male and Female GH-Deficient Mice: An Improved Human GH? Endocrinology 161 (8), bqaa097. doi:10.1210/endocr/bqaa097
List E. O., Berryman D. E., Buchman M., Jensen E. A., Funk K., Duran-Ortiz S., et al. (2019). GH Knockout Mice Have Increased Subcutaneous Adipose Tissue With Decreased Fibrosis and Enhanced Insulin Sensitivity. Endocrinology 160 (7), 1743–1756. doi:10.1210/en.2019-00167
List E. O., Berryman D. E., Funk K., Jara A., Kelder B., Wang F., et al. (2014). Liver-specific GH Receptor Gene-Disrupted (LiGHRKO) Mice Have Decreased Endocrine IGF-I, Increased Local IGF-I, and Altered Body Size, Body Composition, and Adipokine Profiles. Endocrinology 155 (5), 1793–1805. doi:10.1210/en.2013-2086
List E. O., Berryman D. E., Ikeno Y., Hubbard G. B., Funk K., Comisford R., et al. (2015). Removal of Growth Hormone Receptor (GHR) in Muscle of Male Mice Replicates Some of the Health Benefits Seen in Global GHR−/− Mice. Aging 7 (7), 500–512. doi:10.18632/aging.100766
Liu Z., Han T., Werner H., Rosen C. J., Schaffler M. B., Yakar S. (2018). Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass. J. Bone Min. Res. 33 (1), 123–136. doi:10.1002/jbmr.3290
Liu Z., Kennedy O. D., Cardoso L., Basta‐Pljakic J., Partridge N. C., Schaffler M. B., et al. (2016). DMP‐1 ‐mediated Ghr Gene Recombination Compromises Skeletal Development and Impairs Skeletal Response to Intermittent PTH. FASEB J. 30 (2), 635–652. doi:10.1096/fj.15-275859
Loher H., Jenni S., Bucher J., Krüsi M., Kreis R., Boesch C., et al. (2018). Impaired Repletion of Intramyocellular Lipids in Patients with Growth Hormone Deficiency after a Bout of Aerobic Exercise. Growth Hormone IGF Res. 42-43, 32–39. doi:10.1016/j.ghir.2018.08.001
Longobardi S., Di Somma C., Di Relia F., Angelillo N., Ferone D., Colao A., et al. (1998). Bone Mineral Density and Circulating Cytokines in Patients with Acromegaly. J. Endocrinol. Invest 21 (10), 688–693. doi:10.1007/BF03350799
Lopes A. J., Ferreira A. S., Walchan E. M., Soares M. S., Bunn P. S., Guimarães F. S. (2016). Explanatory Models of Muscle Performance in Acromegaly Patients Evaluated by Knee Isokinetic Dynamometry: Implications for Rehabilitation. Hum. Mov. Sci. 49, 160–169. doi:10.1016/j.humov.2016.07.005
Lozier N. R., Kopchick J. J., de Lacalle S. (2018). Relative Contributions of Myostatin and the GH/IGF-1 Axis in Body Composition and Muscle Strength. Front. Physiol. 9, 1418. doi:10.3389/fphys.2018.01418
Lupu F., Terwilliger J. D., Lee K., Segre G. V., Efstratiadis A. (2001). Roles of Growth Hormone and Insulin-like Growth Factor 1 in Mouse Postnatal Growth. Dev. Biol. 229 (1), 141–162. doi:10.1006/dbio.2000.9975
Luque R. M., Lin Q., Córdoba-Chacón J., Subbaiah P. V., Buch T., Waisman A., et al. (2011). Metabolic Impact of Adult-Onset, Isolated, Growth Hormone Deficiency (AOiGHD) Due to Destruction of Pituitary Somatotropes. Plos One 6 (1), e15767. doi:10.1371/journal.pone.0015767
Ma F., Wei Z., Shi C., Gan Y., Lu J., Frank S. J., et al. (2011). Signaling Cross Talk between Growth Hormone (GH) and Insulin-like Growth Factor-I (IGF-I) in Pancreatic Islet β-Cells. Mol. Endocrinol. 25 (12), 2119–2133. doi:10.1210/me.2011-1052
Martel-Duguech L., Alonso-Pérez J., Bascuñana H., Díaz-Manera J., Llauger J., Nuñez-Peralta C., et al. (2021). Intramuscular Fatty Infiltration and Physical Function in Controlled Acromegaly. Eur. J. Endocrinol. 185 (1), 167–177. doi:10.1530/EJE-21-0209
Mastaglia F. L., Barwick D. D., Hall R. (1970). Myopathy in Acromegaly. Lancet 296 (7679), 907–909. doi:10.1016/s0140-6736(70)92072-6
Mathews L. S., Hammer R. E., Behringer R. R., D'Ercole A. J., Bell G. I., Brinster R. L., et al. (1988). Growth Enhancement of Transgenic Mice Expressing Human Insulin-like Growth Factor I. Endocrinology 123 (6), 2827–2833. doi:10.1210/endo-123-6-2827
Mavalli M. D., DiGirolamo D. J., Fan Y., Riddle R. C., Campbell K. S., van Groen T., et al. (2010). Distinct Growth Hormone Receptor Signaling Modes Regulate Skeletal Muscle Development and Insulin Sensitivity in Mice. J. Clin. Invest. 120 (11), 4007–4020. doi:10.1172/JCI42447
Melmed S. (2009). Acromegaly Pathogenesis and Treatment. J. Clin. Invest. 119 (11), 3189–3202. doi:10.1172/JCI39375
Miller A., Doll H., David J., Wass J. (2008). Impact of Musculoskeletal Disease on Quality of Life in Long-Standing Acromegaly. Eur. J. Endocrinol. 158 (5), 587–593. doi:10.1530/EJE-07-0838
Miller W. L., Eberhardt N. L. (1983). Structure and Evolution of the Growth Hormone Gene Family. Endocr. Rev. 4 (2), 97–130. doi:10.1210/edrv-4-2-97
Møller N., Jørgensen J. O. L. (2009). Effects of Growth Hormone on Glucose, Lipid, and Protein Metabolism in Human Subjects. Endocr. Rev. 30 (2), 152–177. doi:10.1210/er.2008-0027
Moller N., Schmitz O., Joorgensen J. O., Astrup J., Bak J. F., Christensen S. E., et al. (1992). Basal- and Insulin-Stimulated Substrate Metabolism in Patients with Active Acromegaly before and after Adenomectomy. J. Clin. Endocrinol. Metabolism 74 (5), 1012–1019. doi:10.1210/jcem.74.5.156914810.1210/jc.74.5.1012
Muñoz-Guerra M., Delgado-Baeza E., Sánchez-Hernández J., García-Ruiz J. (2004). Chondrocyte Cloning in Aging and Osteoarthritis of the Hip cartilageMorphometric Analysis in Transgenic Mice Expressing Bovine Growth Hormone. Acta Orthop. Scand. 75 (2), 210–216. doi:10.1080/00016470412331294475
Murray R. D., Columb B., Adams J. E., Shalet S. M. (2004). Low Bone Mass Is an Infrequent Feature of the Adult Growth Hormone Deficiency Syndrome in Middle-Age Adults and the Elderly. J. Clin. Endocrinol. Metabolism 89 (3), 1124–1130. doi:10.1210/jc.2003-030685
Nagulesparen M., Trickey R., Davies M. J., Jenkins J. S. (1976). Muscle Changes in Acromegaly. Br. Med. J. 2 (6041), 914–915. doi:10.1136/bmj.2.6041.914
Ohlsson C., Bengtsson B.-A., Isaksson O. G. P., Andreassen T. T., Slootweg M. C. (1998). Growth Hormone and Bone. Endocr. Rev. 19 (1), 55–79. doi:10.1210/edrv.19.1.0324
Ohlsson C., Mellström D., Carlzon D., Orwoll E., Ljunggren Ö., Karlsson M. K., et al. (2011). Older Men with Low Serum IGF-1 Have an Increased Risk of Incident Fractures: the MrOS Sweden Study. J. Bone Min. Res. 26 (4), 865–872. doi:10.1002/jbmr.281
Olarescu N. C., Gunawardane K., Hansen T. K., Moller N., Jorgensen J. O. L. (2000). in Normal Physiology of Growth Hormone in Adults. Editors K. R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, W. W. de Herder, K. Dhatariyaet al. South Dartmouth (MA).
Ozturk Gokce B., Gogus F., Bolayir B., Tecer D., Gokce O., Eroglu Altinova A., et al. (2020). The Evaluation of the Tendon and Muscle Changes of Lower Extremity in Patients with Acromegaly. Pituitary 23 (4), 338–346. doi:10.1007/s11102-020-01037-z
Papadakis M. A., Grady D., Black D., Tierney M. J., Gooding G. A., Schambelan M., et al. (1996). Growth Hormone Replacement in Healthy Older Men Improves Body Composition but Not Functional Ability. Ann. Intern Med. 124 (8), 708–716. doi:10.7326/0003-4819-124-8-199604150-00002
Poudel S. B., Dixit M., Yildirim G., Cordoba‐Chacon J., Gahete M. D., Yuji I., et al. (2021). Sexual Dimorphic Impact of Adult‐onset Somatopause on Life Span and Age‐induced Osteoarthritis. Aging Cell 20 (8), e13427. doi:10.1111/acel.13427
Reyes-Vidal C. M., Mojahed H., Shen W., Jin Z., Arias-Mendoza F., Fernandez J. C., et al. (2015). Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment. J. Clin. Endocrinol. Metabolism 100 (8), 2946–2955. doi:10.1210/jc.2015-1917
Riggs B. L., Randall R. V., Wahner H. W., Jowsey J., Kelly P. J., Singh M. (1972). The Nature of the Metabolic Bone Disorder in Acromegaly. J. Clin. Endocrinol. Metabolism 34 (6), 911–918. doi:10.1210/jcem-34-6-911
Rosén T., Hansson T., Granhed H., Szucs J., Bengtsson B.-Å. (1993). Reduced Bone Mineral Content in Adult Patients with Growth Hormone Deficiency. Acta Endocrinol. (Copenh) 129 (3), 201–206. doi:10.1530/acta.0.1290201
Rosen T., Wilhelmsen L., Landin-Wilhelmsen K., Lappas G., Bengtsson B. (1997). Increased Fracture Frequency in Adult Patients with Hypopituitarism and GH Deficiency. Eur. J. Endocrinol. 137 (3), 240–245. doi:10.1530/eje.0.1370240
Rutherford O. M., Beshyah S. A., Schott J., Watkins Y., Johnston D. G. (1995). Contractile Properties of the Quadriceps Muscle in Growth Hormone-Deficient Hypopituitary Adults. Clin. Sci. (Lond) 88 (1), 67–71. doi:10.1042/cs0880067
Saaf M., Hilding A., Thoren M., Troell S., Hall K. (1999). Growth Hormone Treatment of Osteoporotic Postmenopausal Women - a One-Year Placebo-Controlled Study. Eur. J. Endocrinol. 140 (5), 390–399. doi:10.1530/eje.0.1400390
Salomon F., Cuneo R. C., Hesp R., Sönksen P. H. (1989). The Effects of Treatment with Recombinant Human Growth Hormone on Body Composition and Metabolism in Adults with Growth Hormone Deficiency. N. Engl. J. Med. 321 (26), 1797–1803. doi:10.1056/NEJM198912283212605
Schuenke M. D., Kopchick J. J., Hikida R. S., Kraemer W. J., Staron R. S. (2008). Effects of Growth Hormone Overexpression vs. Growth Hormone Receptor Gene Disruption on Mouse Hindlimb Muscle Fiber Type Composition. Growth Hormone IGF Res. 18 (6), 479–486. doi:10.1016/j.ghir.2008.04.003
Seeman E., Wahner H. W., Offord K. P., Kumar R., Johnson W. J., Riggs B. L. (1982). Differential Effects of Endocrine Dysfunction on the Axial and the Appendicular Skeleton. J. Clin. Invest. 69 (6), 1302–1309. doi:10.1172/jci110570
Segard H. B., Moulin S., Boumard S., de Crémiers C. A., Kelly P. A., Finidori J. (2003). Autocrine Growth Hormone Production Prevents Apoptosis and Inhibits Differentiation in C2C12 Myoblasts. Cell. Signal. 15 (6), 615–623. doi:10.1016/s0898-6568(03)00005-6
Sims N. A., Clément-Lacroix P., Da Ponte F., Bouali Y., Binart N., Moriggl R., et al. (2000). Bone Homeostasis in Growth Hormone Receptor-Null Mice Is Restored by IGF-I but Independent of Stat5. J. Clin. Invest. 106 (9), 1095–1103. doi:10.1172/JCI10753
Sjögren K., Bohlooly Y. M., Olsson B., Coschigano K., Törnell J., Mohan S., et al. (2000). Disproportional Skeletal Growth and Markedly Decreased Bone Mineral Content in Growth Hormone Receptor −/− Mice. Biochem. Biophysical Res. Commun. 267 (2), 603–608. doi:10.1006/bbrc.1999.1986
Solomon G., Reicher S., Gussakovsky E. E., Jomain J.-B., Gertler A. (2006). Large-scale Preparation and In Vitro Characterization of Biologically Active Human Placental (20 and 22K) and Pituitary (20K) Growth Hormones: Placental Growth Hormones Have No Lactogenic Activity in Humans. Growth Hormone IGF Res. 16 (5-6), 297–307. doi:10.1016/j.ghir.2006.07.002
Sotiropoulos A., Ohanna M., Kedzia C., Menon R. K., Kopchick J. J., Kelly P. A., et al. (2006). Growth Hormone Promotes Skeletal Muscle Cell Fusion Independent of Insulin-like Growth Factor 1 Up-Regulation. Proc. Natl. Acad. Sci. U.S.A. 103 (19), 7315–7320. doi:10.1073/pnas.0510033103
Taaffe D. R., Pruitt L., Reim J., Hintz R. L., Butterfield G., Hoffman A. R., et al. (1994). Effect of Recombinant Human Growth Hormone on the Muscle Strength Response to Resistance Exercise in Elderly Men. J. Clin. Endocrinol. Metabolism 79 (5), 1361–1366. doi:10.1210/jcem.79.5.7525633
Toogood A. A., Adams J. E., O'Neill P. A., Shalet S. M. (1997). Elderly Patients with Adult-Onset Growth Hormone Deficiency Are Not Osteopenic. J. Clin. Endocrinol. Metabolism 82 (5), 1462–1466. doi:10.1210/jcem.82.5.393210.1210/jc.82.5.1462
Tornero J., Castaneda S., Vidal J., Herrero-Beaumont G. (1990). Differences between Radiographic Abnormalities of Acromegalic Arthropathy and Those of Osteoarthritis. Arthritis & Rheumatism 33 (3), 455–456. doi:10.1002/art.1780330332
Urbanek M., Russell J. E., Cooke N. E., Liebhaber S. A. (1993). Functional Characterization of the Alternatively Spliced, Placental Human Growth Hormone Receptor. J. Biol. Chem. 268 (25), 19025–19032. doi:10.1016/s0021-9258(17)46730-5
Vaňuga P., Kužma M., Stojkovičová D., Smaha J., Jackuliak P., Killinger Z., et al. (2021). The Long-Term Effects of Growth Hormone Replacement on Bone Mineral Density and Trabecular Bone Score: Results of the 10-Year Prospective Follow-Up. Physiol. Res. 70 (Suppl. 1), S61–S68. doi:10.33549/physiolres.934775
Venken K., Movérare-Skrtic S., Kopchick J. J., Coschigano K. T., Ohlsson C., Boonen S., et al. (2007). Impact of Androgens, Growth Hormone, and IGF-I on Bone and Muscle in Male Mice during Puberty. J. Bone Min. Res. 22 (1), 72–82. doi:10.1359/jbmr.060911
Vickers M. H., Gilmour S., Gertler A., Breier B. H., Tunny K., Waters M. J., et al. (2009). 20-kDa Placental hGH-V Has Diminished Diabetogenic and Lactogenic Activities Compared with 22-kDa hGH-N while Retaining Antilipogenic Activity. Am. J. Physiology-Endocrinology Metabolism 297 (3), E629–E637. doi:10.1152/ajpendo.00221.2009
Vijayakumar A., Wu Y., Sun H., Li X., Jeddy Z., Liu C., et al. (2012). Targeted Loss of GHR Signaling in Mouse Skeletal Muscle Protects against High-Fat Diet-Induced Metabolic Deterioration. Diabetes 61 (1), 94–103. doi:10.2337/db11-0814
Wassenaar M. J. E., Biermasz N. R., Pereira A. M., van der Klaauw A. A., Smit J. W. A., Roelfsema F., et al. (2009). The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly. J. Clin. Endocrinol. Metab. 94 (12), 4671–4678. doi:10.1210/jc.2009-1172
Whitehead H. M., Gilliland J. S., Allen I. V., Hadden D. R. (1989). Growth Hormone Treatment in Adults with Growth Hormone Deficiency: Effect on Muscle Fibre Size and Proportions. Acta Paediatr. 78, 6573–6764. discussion 68. doi:10.1111/j.1651-2227.1989.tb11246.x
Wolf E., Rapp K., Brem G. (1991). Expression of Metallothionein-Human Growth Hormone Fusion Genes in Transgenic Mice Results in Disproportionate Skeletal Gigantism. Growth Dev. Aging 55 (2), 117–127.
Wolf E., Wanke R., Schenck E., Hermanns W., Brem G. (1995). Effects of Growth Hormone Overproduction on Grip Strength of Transgenic Mice. Eur. J. Endocrinol. 133 (6), 735–740. doi:10.1530/eje.0.1330735
Wüster C., Abs R., Bengtsson B.-Å., Bennmarker H., Feldt-Rasmussen U., Hernberg-Ståhl E., et al. (2001). The Influence of Growth Hormone Deficiency, Growth Hormone Replacement Therapy, and Other Aspects of Hypopituitarism on Fracture Rate and Bone Mineral Density. J. Bone Min. Res. 16 (2), 398–405. doi:10.1359/jbmr.2001.16.2.398
Yakar S., Isaksson O. (2016). Regulation of Skeletal Growth and Mineral Acquisition by the GH/IGF-1 axis: Lessons from Mouse Models. Growth Hormone IGF Res. 28, 26–42. doi:10.1016/j.ghir.2015.09.004
Yakar S., Liu J.-L., Stannard B., Butler A., Accili D., Sauer B., et al. (1999). Normal Growth and Development in the Absence of Hepatic Insulin-like Growth Factor I. Proc. Natl. Acad. Sci. U.S.A. 96 (13), 7324–7329. doi:10.1073/pnas.96.13.7324
Keywords: somatopause, osteoarthritis, sarcopenia, growth hormone, acromegaly, growth hormone deficiency (GHD)
Citation: Young JA, Zhu S, List EO, Duran-Ortiz S, Slama Y and Berryman DE (2022) Musculoskeletal Effects of Altered GH Action. Front. Physiol. 13:867921. doi: 10.3389/fphys.2022.867921
Received: 01 February 2022; Accepted: 25 April 2022;
Published: 19 May 2022.
Edited by:
Henriette Uhlenhaut, Helmholtz Association of German Research Centres (HZ), GermanyReviewed by:
Javier Durán, Heidelberg University Hospital, GermanyCarlos Arámburo, National Autonomous University of Mexico, Mexico
Copyright © 2022 Young, Zhu, List, Duran-Ortiz, Slama and Berryman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Darlene E. Berryman, berrymad@ohio.edu